When bringing a new drug product to market, drug sponsors are faced with whether to build a new facility or partner with a CDMO. Drug discovery speed coupled with new advances in regulatory approval strategies are decreasing time to market and leading to CDMO backlogs. Drug sponsors are now considering building their own facilities that are CDMO-like ballroom designs. Once a drug sponsor decides to build its own facility then the primary decision becomes: are you designing a nimble facility or are you designing a quick facility? This presentation will discuss common pitfalls encountered during project execution and how to make sure when delivering the project that there are no surprises.